News | News By Subject | News by Disease News By Date | Search News

Myelodysplastic syndrome News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Shire (SHPG) Pays CTI BioPharma $10.3 Million to Terminate Cancer Deal it Picked Up From Baxalta (BXLT)     10/25/2016
Baxalta (BXLT) Kills Cancer Drug Development Deal With Onconova (ONTX)     3/4/2016
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Onconova Therapeutics Inc. (ONTX) Tanks Following Disappointing Phase 3 Rigosertib Results     2/21/2014
UK Cost Body Endorses Celgene (CELG) Blood Cancer Drug     2/17/2011
FDA Approves Eisai Inc. (ESALF.PK)'s Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS)     3/12/2010
SuperGen, Inc. (SUPG) (JOBS) Drug Dacogen Fails Trial; Likely Delay to European Nod     7/2/2008
Eisai Corporation of North America Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes     7/2/2008
Study of Celgene Corporation (CELG)'s VIDAZA(R) in Higher-Risk Myelodysplastic Syndrome Patients Demonstrates Improved Overall Survival     6/3/2008
Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts) (MLNM) Announces Publication of Clinical Results Underscores VELCADE(R) for Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients     3/13/2008
Celgene (CELG) European Panel Recommends Against Revlimid for MDS     1/25/2008
Pharmion Corporation (PHRM) Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)     1/14/2008
Pharmion Corporation (PHRM) and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study     12/11/2007
Pharmion Corporation (PHRM) (Jobs) Drug Vidaza Extends Life; Shares Soar     8/2/2007

News from Around the Web

Press Releases
FDA Lifts Clinical Hold On Seattle Genetics (SGEN)’ Cancer Drug Trial     3/6/2017
Syros Pharma Presents Data At American Society of Hematology Annual Meeting Further Supporting Clinical Potential Of Its First-In-Class Selective Rara Agonist For Genomically Defined Subsets Of AML And MDS Patients     12/5/2016
Cellerant Therapeutics, Inc. Awarded $1.5 Million SBIR Contract For Development Of Novel Antibody-Based Therapeutic Against IL1RAP     9/26/2016
Syros Pharma Announces First Patient Enrolled In Phase II Clinical Trial Of SY-1425 In Genomically Defined Patients With Acute Myeloid Leukemia Or Myelodysplastic Syndrome     9/22/2016
REPEAT/Janssen-Cilag International NV (JNJ)’s EPREX (Epoetin Alfa) Demonstrates Effectiveness As A Treatment For Anaemia In Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndromes     6/13/2016
Acceleron Pharma And Celgene (CELG) Announce Updated Results From An Ongoing Phase II Study Of Luspatercept In Myelodysplastic Syndromes At The 21st Congress Of The European Hematology Association     6/10/2016
Mylan (MYL) Launches Generic Vidaza Injection     6/2/2016
Acceleron Pharma Announces Data Presentations With Luspatercept At The 21st Congress Of The European Hematology Association     5/19/2016
Acceleron Pharma Reports First Quarter 2016 Financial And Operational Results     5/5/2016
Seattle Genetics (SGEN) Reports First Quarter 2016 Financial Results     4/29/2016
Seattle Genetics (SGEN) Initiates Phase I/II Trial Of Vadastuximab Talirine (SGN-CD33A) Combination Therapy For Patients With Untreated Myelodysplastic Syndrome (MDS)     2/22/2016
Geron Corporation (GERN) Announces Initiation Of Janssen Phase II/III Clinical Trial Of Imetelstat In Myelodysplastic Syndromes     1/14/2016
Rich Pharma Receives FDA Approval For A Phase 1/2 Study In AML & MDS     12/28/2015
Sunesis (SNSS) Announces Presentation Of Results From Washington University Sponsored Phase 1/2 Trial Of Vosaroxin In MDS And VALOR Analysis Of Baseline Safety Predictors At Washington University Annual Meeting     12/7/2015
TetraLogic Pharmaceuticals (TLOG) Announces Clinical Data On Birinapant To Be Presented At The 57th Annual American Society of Hematology Annual Meeting     11/9/2015